Clinical Trial: A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 >= 50%. (ROSETTA Lung-202)

U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07361510) titled 'A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 >= 50%. (ROSETTA Lung-202)' on Jan. 21.

Brief Summary: The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 >= 50%.

Study Start Date: April 09, 2026

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer (NSCLC)

Intervention: DRUG: Pumitamig

Specified dose on specified days

DRUG: Pembrolizumab

Specified dose on specified days

Recruitment St...